Previous close | 1.0000 |
Open | 1.2500 |
Bid | 1.1000 |
Ask | 1.4000 |
Strike | 55.00 |
Expiry date | 2023-06-16 |
Day's range | 1.2500 - 1.2500 |
Contract range | N/A |
Volume | |
Open interest | 3.52k |
Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.
Sanofi's (SNY) Dupixent succeeds in a pivotal study for COPD. FDA gives CRL to AbbVie's (ABBV) Parkinson's disease therapy, ABBV-951
Shares of drugmakers Sanofi and Regeneron surged more than 6% on Mar 23 on COPD drug data.